Pfizer Files IPR Challenge to UniQure Hemophilia Patents

May 11, 2021, 7:48 PM

Pfizer claims UniQure patents 10,465,180 and 9,982,248 don’t contain new ideas and should be canceled by the Patent Trial and Appeal Board.

  • The patents cover a gene therapy involving nucleic acids that encode for a variant of a human protein called factor IX; Pfizer says it was disclosed a decade earlier by scientists with the University of North Carolina
  • Pfizer had challenged related UniQure patent, 9,249,405 last year; the case was terminated after UniQure “effectively conceded”
    • Pfizer said its argument in the new cases are the same, which “dooms” the two patents “as those claims are either directed to that ...

To read the full article log in. To learn more about a subscription click here.